/BBNX
BBNX Stock - Beta Bionics, Inc.
Healthcare|Medical - Equipment & ServicesNASDAQ
$29.25+0.65%
+$0.19 (+0.65%) • Dec 19
56
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.99
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).60
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+5.2%upside
Target: $30.77
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BBNX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$28.96 – $29.54
TARGET (TP)$30.78
STOP LOSS$26.91
RISK/REWARD1:0.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta5.72
52W High$32.71
52W Low$8.89
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $65.12M | $11.99M | $179,000 |
| Gross Profit | $35.89M | $6.31M | $179,000 |
| Gross Margin | 55.1% | 52.6% | 100.0% |
| Operating Income | $-45,251,000 | $-35,850,000 | $-65,844,000 |
| Net Income | $-54,756,000 | $-44,099,000 | $-64,751,000 |
| Net Margin | -84.1% | -367.6% | -36173.7% |
| EPS | $-8.60 | $-8.31 | $-12.96 |
Company Overview
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
9
75%
Hold / Neutral
3
25%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
9 Bullish3 Neutral/Bearish
Price Targets
$24
Average Target
↓ 16.5% Downside
Now
$16
Low
$24
Average
$30
High
Based on 12 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 21st 2025 | Stifel | Resumed | Buy | $26 |
| October 1st 2025 | Goldman | Upgrade | Buy | $26 |
| June 16th 2025 | Truist | Initiation | Buy | $26 |
| June 12th 2025 | Lake Street | Initiation | Buy | $30 |
| May 30th 2025 | Goldman | Initiation | Neutral | $16 |
| May 30th 2025 | Wolfe Research | Initiation | Outperform | $20 |
| February 24th 2025 | BofA Securities | Initiation | Buy | - |
| February 24th 2025 | Lake Street | Initiation | Buy | $30 |
| February 24th 2025 | Stifel | Initiation | Buy | $25 |
| February 24th 2025 | Piper Sandler | Initiation | Overweight | $26 |
| February 24th 2025 | Leerink Partners | Initiation | Outperform | $28 |
| February 20th 2025 | Ladenburg Thalmann | Initiation | Neutral | $20 |
| February 20th 2025 | Robert W. Baird | Initiation | Neutral | $20 |
Earnings History & Surprises
BBNXBeat Rate
50%
Last 4 quarters
Avg Surprise
-71.3%
EPS vs Estimate
Beats / Misses
2/2
Last 12 quarters
Latest EPS
$-0.33
Q4 2025
EPS Surprise History
Q3 23
No data
Q4 23
No data
Q1 25
No data
Q1 25
-333.3%
$-1.82vs$-0.42
Q2 25
-2.0%
$-0.52vs$-0.51
Q3 25
+23.5%
$-0.39vs$-0.51
Q4 25
+26.7%
$-0.33vs$-0.45
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 24, 2026 | $-0.45 | — | — | — |
Q4 2025 | Oct 28, 2025 | $-0.45 | $-0.33 | +26.7% | ✓ BEAT |
Q3 2025 | Jul 29, 2025 | $-0.51 | $-0.39 | +23.5% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-0.51 | $-0.52 | -2.0% | ✗ MISS |
Q1 2025 | Mar 25, 2025 | $-0.42 | $-1.82 | -333.3% | ✗ MISS |
Q1 2025 | Jan 31, 2025 | — | $-1.55 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-3.13 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-1.71 | — | — |
Latest News
Truist Securities Maintains Buy on Beta Bionics, Raises Price Target to $37
📈 PositiveBenzinga•Dec 18, 2025, 02:18 PM
Goldman Sachs Maintains Buy on Beta Bionics, Raises Price Target to $33
📈 PositiveBenzinga•Oct 29, 2025, 06:00 PM
Truist Securities Reiterates Buy on Beta Bionics, Raises Price Target to $32
📈 PositiveBenzinga•Oct 29, 2025, 02:59 PM
Piper Sandler Reiterates Overweight on Beta Bionics, Raises Price Target to $32
📈 PositiveBenzinga•Oct 29, 2025, 01:27 PM
Beta Bionics shares are trading higher after the company reported better-than-expected Q3 financial results.
📈 PositiveBenzinga•Oct 29, 2025, 10:46 AM
Beta Bionics Raises FY2025 Sales Guidance from $88.000M-$93.000M to $96.500M vs $91.355M Est
📈 PositiveBenzinga•Oct 28, 2025, 08:04 PM
Beta Bionics Q3 EPS $(0.33) Beats $(0.44) Estimate, Sales $27.253M Beat $23.972M Estimate
📈 PositiveBenzinga•Oct 28, 2025, 08:02 PM
Goldman Sachs Upgrades Beta Bionics to Buy, Raises Price Target to $26
📈 PositiveBenzinga•Oct 1, 2025, 05:32 PM
Truist Securities Maintains Buy on Beta Bionics, Raises Price Target to $28
📈 PositiveBenzinga•Sep 22, 2025, 01:59 PM
Frequently Asked Questions about BBNX
What is BBNX's current stock price?
Beta Bionics, Inc. (BBNX) is currently trading at $29.25 per share. The stock has moved +0.65% today.
What is the analyst price target for BBNX?
The average analyst price target for BBNX is $30.78, based on 1 analyst.
What sector is Beta Bionics, Inc. in?
Beta Bionics, Inc. operates in the Healthcare sector, specifically within the Medical - Equipment & Services industry. The company is traded on the NASDAQ exchange.
What is BBNX's market cap?
Beta Bionics, Inc. has a market capitalization of $1.29 billion, making it a small-cap company.
Does BBNX pay dividends?
No, Beta Bionics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAHCO
AdaptHealth Corp.
$9.97
Mkt Cap: $1.4B
DVAX
Dynavax Technologies Corporation
$10.86
Mkt Cap: $1.3B
IMTX
Immatics N.V.
$10.27
Mkt Cap: $1.2B
KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD.
$27.32
Mkt Cap: $1.6B
ORIC
ORIC Pharmaceuticals, Inc.
$8.04
Mkt Cap: $0.8B
PGEN
Precigen, Inc.
$4.32
Mkt Cap: $1.3B
PLSE
Pulse Biosciences, Inc.
$15.26
Mkt Cap: $1.0B
STAA
STAAR Surgical Company
$25.14
Mkt Cap: $1.2B
TERN
Terns Pharmaceuticals, Inc.
$39.90
Mkt Cap: $3.6B
TRML
Tourmaline Bio, Inc.
$47.98
Mkt Cap: $1.2B
Explore stocks similar to BBNX for comparison